Loading...
Loading...
KNTE| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 32.7M |
| Operating I/L | -32.7M |
| Other Income/Expense | 1.1M |
| Interest Income | 0.0M |
| Pretax | -31.6M |
| Income Tax Expense | -1.6M |
| Net Income/Loss | -29.9M |
Kinnate Biopharma Inc. is a biopharmaceutical company specializing in the discovery and development of small molecule kinase inhibitors for the treatment of genomically defined cancers. The company's product portfolio includes KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors targeting cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs such as the Cyclin-Dependent Kinase 12 (CDK12) inhibitor in its KIN004 program.
